Mubadala Investment Company, a global sovereign investment company based in Abu Dhabi, has successfully acquired 100% ownership of a business unit of UCB Pharma in China in partnership with CBC Group, Asia’s largest healthcare-dedicated asset management group.

UCB is a global biopharmaceutical company based in Belgium, leading the market in immunology, neurology, and rare diseases, a rapidly growing market in China. The company is strategically positioned to expand its central nervous system drug portfolio.

The acquisition includes UCB’s neurology drug portfolio, including Keppra®, Vimpat®, Neupro, and the allergy drugs Zyrtec® and Xyzal® in mainland China, as well as a manufacturing site in Zhuhai, China. The combined net sales of these drugs in China amounted to €131 million in 2023.

The deal is expected to close in the fourth quarter of 2024, subject to the fulfillment of certain conditions, including obtaining the necessary antitrust approvals and other customary conditions. This investment aligns with Mubadala’s strategy to enhance its presence in Asia through selected investments in various sectors with strong growth potential. Healthcare, particularly pharmaceutical acquisitions, is a top priority for this investment strategy.